Sunlenca, the first twice-yearly HIV therapy, approved by European Commission
The European Commission (EC) has granted Marketing Authorization for the first twice-yearly HIV therapy, Sunlenca (lenacapavir), developed by Gilead Sciences, the biopharmaceutical company announced […]
Sunlenca, the first twice-yearly HIV therapy, approved by European Commission Read More »